Superworth

Inovio Pharmaceuticals price to sales ratio INO

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
n/m
not in our data today
Last meaningful
183×
Aug 2025
10-year median
13.5×
10-year range
7.4× to 199×
Peer median
1.4×

Inovio Pharmaceuticals has no meaningful price to sales ratio today: it is not in our data for Oct 23, 2026.

It was last meaningful in Aug 2025, at 183×.

On the days it had one over the last ten years, its median was 13.5×, from 7.4× in May 2019 to 199× in Dec 2021.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2025183×172×190×
2024180×134×180×
2023163×10.3×163×
202235.5×34.8×190×
2021161×161×199×
202067.6×47.0×71.5×
201952.7×7.4×52.7×
201810.4×8.8×13.9×
20178.9×8.9×16.4×
201615.7×9.9×18.7×
201513.1×12.1×60.1×
201458.2×32.6×68.4×
201345.8×16.0×109×
201214.8×6.4×16.3×

Against its peers

Companies in Drug Manufacturers - General nearest Inovio Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
INOInovio Pharmaceuticalsn/m
LFVNLifevantage0.4×
SPROSpero Therapeutics1.4×
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products0.4×
ARVNArvinas1.5×
PBYIPuma Biotechnology2.5×
IRWDIronwood Pharmaceuticals1.5×
ZVRAZevra Therapeutics4.3×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical0.9×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Inovio Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.